[In vitro and in vivo activity of a combination of clavulanic acid and amoxicillin against Klebsiella pneumoniae producing extended broad-spectrum betalactamase (CTX-1, SHV-3, SHV-4)].
In vitro activity of an aminopenicillin (amoxicillin or ampicillin) combined with a betalactamase inhibitor (clavulanic acid or sulbactam, 2 mg/l) was examined against 39 strains of K. pneumoniae producing 3 types of extended broad spectrum betalactamases (CTX-1, SHV-3, SHV-4). Clavulanic acid produces the best synergistic effect. The in vivo activity of Augmentin (amoxicillin + clavulanic acid), 1 g once or twice a day, during 10 +/- 3 days was evaluated on 10 cases urinary tract infections in paraplegic patients. After 3 days, no leucocyturia was observed and bacteria were no more detected. The inhibitory effect of clavulanic acid for the extended broad-spectrum betalactamases shows that such an association could be probably chosen as well for treatment urinary infection.
Migueres
M L
ML
Centre Hospitalier Universitaire Paris-Ouest, Hôpital R.-Poincaré, Garches.
Ronco
E
E
Guenounou
M
M
Philippon
A
A
D000658:Amoxicillin / Q000494:pharmacology* / Q000627:therapeutic use; D000667:Ampicillin / Q000494:pharmacology; D002969:Clavulanic Acids / Q000494:pharmacology* / Q000627:therapeutic use; D004359:Drug Therapy, Combination / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D066298:In Vitro Techniques; D007526:Isoelectric Point; D007711:Klebsiella pneumoniae / Q000187:drug effects* / Q000201:enzymology; D013407:Sulbactam / Q000494:pharmacology; D014552:Urinary Tract Infections / Q000188:drug therapy; D065093:beta-Lactamase Inhibitors; D001618:beta-Lactamases / Q000378:metabolism*
D002969:Clavulanic Acids; D065093:beta-Lactamase Inhibitors; D000667:Ampicillin; D000658:Amoxicillin; D001618:beta-Lactamases; D013407:Sulbactam
Activité in vitro et in vivo de l'association acide clavulanique - amoxicilline chez Klebsiella pneumoniae productrice de bêtalactamase à spectre élargi (CTX-1, SHV-3, SHV-4).